Business Context and Reporting Period
This Form 8-K Current Report was filed by E. I. du Pont de Nemours and Company (DuPont) on February 13, 2017, regarding an event that occurred on February 11, 2017. The filing addresses the settlement of multi-district litigation (MDL) involving approximately 3,550 personal injury lawsuits related to exposure to perfluorooctanoic acid (PFOA) in drinking water. The contamination is linked to the historical manufacture or use of PFOA at the Washington Works plant in Parkersburg, West Virginia, which was previously operated by DuPont and is now owned by The Chemours Company (Chemours).
Key Financial Metrics and Settlement Terms
The filing details a global settlement agreement in principle with plaintiffs' counsel. Key financial terms include:
- Total Settlement Amount: $670.7 million in cash.
- Payment Allocation: The cost is split equally, with DuPont paying $335.35 million and Chemours paying $335.35 million.
- Indemnification: DuPont's payment is not subject to indemnification or reimbursement by Chemours.
- Future Liability Sharing: Following the settlement, DuPont and Chemours agreed to a limited sharing of future PFOA liabilities for five years. Chemours will pay up to $25 million annually; DuPont will pay the next $25 million of excess (non-indemnifiable by Chemours); Chemours bears any further excess.
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period, as this is a current report focused on a specific legal event rather than a periodic financial statement.
Material Changes and Unusual Items
The primary material change is the resolution of the PFOA MDL litigation. The settlement covers all filed and unfiled personal injury cases and claims within the plaintiffs' counsel inventory, including cases tried to a jury verdict. In exchange for the payment, DuPont and Chemours receive a complete release of all claims by settling plaintiffs. The agreement is not an admission of liability or fault. The settlement is not subject to court approval but requires the drafting of a master settlement agreement. DuPont retains a "walk-away" right to terminate the settlement if a specified number of plaintiffs opt out.
Guidance, Outlook, and Risks
The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ due to various risks. Key risks and contingencies identified include:
- Merger Risks: Significant risks related to the proposed all-stock merger with The Dow Chemical Company, including regulatory approvals, integration challenges, and the potential separation of agriculture, material science, and specialty products businesses post-merger.
- Operational and Market Risks: Fluctuations in energy and raw material prices, global economic conditions, currency exchange rates, and supply disruptions.
- Legal and Environmental Risks: Outcomes of other significant litigation and environmental matters, and the realization of associated indemnification assets.
- Settlement Contingencies: The settlement may not proceed if the master agreement cannot be finalized or if the walk-away threshold is triggered.
Investor Verification Checklist
- Verify the final execution of the master settlement agreement and the timing of the $335.35 million cash payment by DuPont.
- Monitor the number of plaintiffs opting out of the settlement to assess if DuPont's "walk-away" right is triggered.
- Review the Separation Agreement between DuPont and Chemours to understand the specific definitions of "indemnifiable losses" for the five-year future liability sharing period.
- Assess the impact of the settlement and ongoing merger with Dow Chemical on DuPont's liquidity and credit rating.
- Confirm whether Chemours has waived defenses regarding punitive damages and attorneys' fees as agreed in the settlement.